
Pharmaceuticals / Healthcare · NSE
Medicamen Organics Limited, founded in 1995, is a trusted pharmaceutical company specializing in the development, manufacturing, and distribution of a wide range of pharmaceutical dosages, including tablets, capsules, syrups, ointments, gels, and dry powders. Catering to both government and private sectors as a contract manufacturer, the company offers 84 products across various therapeutic categories, such as antibacterials, antifungals, antidiabetics, antihypertensives, and multivitamin preparations. Medicamen Organics has a strong domestic presence and exports to multiple international markets, including Africa, CIS, and Southeast Asia. The company operates two WHO-GMP-approved manufacturing facilities in Haridwar, Uttarakhand, spanning 21,536 square feet. With partnerships with 38 domestic contract manufacturers and 12 merchant exporters, the company employed 116 people as of September 30, 2023, ensuring high-quality production and global reach.
Price Band
₹32 – ₹34
Issue Size
₹10.54 Cr
Lot Size
4000 shares
GMP
+205.9%
Est. Listing
₹104
at current GMP
Subscribed
965.49x
overall
Open
21 Jun 2024
Close
25 Jun 2024
Allotment
26 Jun 2024
Refund
27 Jun 2024
Demat Credit
28 Jun 2024
Listing
28 Jun 2024
Designated Registrar: Kfin Technologies Limited
Allotment Date
26 Jun 2024
Basis finalization
Refunds Initiate
27 Jun 2024
Mandate release
Demat Credit
28 Jun 2024
Shares in demat
Listing Debut
28 Jun 2024
Trading begins
Medicamen Organics Limited is bringing an initial public offering (IPO) in the Pharmaceuticals / Healthcare sector with an aggregate issue size of ₹10.54 Crores. The shares are offered at a price band of ₹32 to ₹34 per equity share on NSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 4000 shares (approx. ₹1,36,000 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Allotment reconciliation will be managed by Kfin Technologies Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2024-06-28, while un-allotted funds or UPI block mandates will be released on 2024-06-27.
Allotment records are updated in batches. If the status is not yet available, please wait a few hours until the basis of allotment is fully finalized.
Since funds are blocked under ASBA/UPI, the bank will automatically release the blocked hold on your funds upon receipt of revocation instructions from the sponsor bank.